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Abstract
Lipotoxicity of the heart has been implicated as a leading cause of morbidity in Type 2 Diabetes Mellitus (T2DM).
While numerous reports have demonstrated increased myocardial fatty acid (FA) utilization in obese T2DM animal
models, this diabetic phenotype has yet to be demonstrated in non-obese animal models of T2DM. Therefore, the
present study investigates functional, metabolic, and genomic differences in myocardial FA metabolism in non-obese
type 2 diabetic rats. The study utilized Goto-Kakizaki (GK) rats at the age of 24 weeks. Each rat was imaged with
small animal positron emission tomography (PET) to estimate myocardial blood flow (MBF) and myocardial FA
metabolism. Echocardiograms (ECHOs) were performed to assess cardiac function. Levels of triglycerides (TG) and
non-esterified fatty acids (NEFA) were measured in both plasma and cardiac tissues. Finally, expression profiles for
168 genes that have been implicated in diabetes and FA metabolism were measured using quantitative PCR (qPCR)
arrays. GK rats exhibited increased NEFA and TG in both plasma and cardiac tissue. Quantitative PET imaging
suggests that GK rats have increased FA metabolism. ECHO data indicates that GK rats have a significant increase
in left ventricle mass index (LVMI) and decrease in peak early diastolic mitral annular velocity (E’) compared to
Wistar rats, suggesting structural remodeling and impaired diastolic function. Of the 84 genes in each the diabetes
and FA metabolism arrays, 17 genes in the diabetes array and 41 genes in the FA metabolism array were
significantly up-regulated in GK rats. Our data suggest that GK rats’ exhibit increased genomic disposition to FA and
TG metabolism independent of obesity.
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Introduction
Type 2 Diabetes Mellitus (T2DM) is a complex,
heterogeneous, polygenic disease that affects more than 150
million people worldwide [1]. Recent epidemiological and
experimental evidence suggests that there is a close link
between the pathogenesis of obesity and T2DM [2], thus
confounding the bleak outlook for T2DM. Cardiovascular
disease is the leading cause of death among diabetic patients
[3,4], attributed to impairment in heart muscle contraction,
particularly abnormalities in diastolic function [5]. Although
several theories have been put forth, evidence has emerged
that severe alterations in myocardial energy metabolism may
explain deficiencies in cardiac function among diabetic patients
[6]. In particular, insulin resistance in the onset of T2DM shifts
the balance of substrate utilization such that the diabetic heart
relies almost exclusively on fatty acids (FA) for its energy
needs [7]. High rates of FA utilization result in accumulation of
myocardial lipids and lipid intermediates leading to lipotoxicity
of the heart [8]. Notwithstanding the link between obesity and
T2DM, however, it is often neglected that a significant fraction
of the population with T2DM, by some accounts 20%, is non-
obese [9].
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Indeed, obesity is recognized as an independent risk factor
for cardiovascular disease [10]. However, numerous studies
have shown that non-obese patients with T2DM have a risk of
cardiovascular diseases (CVD) similar to that of obese patients
[11,12]. In obesity, elevated plasma non-esterified fatty acids
(NEFA) levels have been implicated as one of the primary
causes for insulin-resistance and downstream consequences
[13]. The interplay between increased peripheral NEFA levels,
obesity, and diabetes has been studied extensively [14-16].
However, the interplay between diabetes and myocardial
substrate utilization in the non-obese state has received limited
scrutiny. In a recent work, Desrois and colleagues
demonstrated reduced insulin-stimulated glucose uptake in
Goto-Kakizaki (GK) rats, a polygenic animal model of non-
obese T2DM [17,18]. The authors attributed the decrease in
glucose uptake to decreased GLUT4, insulin receptor-β-subunit
and insulin receptor substrate-1 protein levels. Given that
increased supply and delivery of FA plays a significant role in
the pathogenesis of diabetic cardiovascular disease in obese
individuals and animal models of obesity, we sought to
characterize the interplay between myocardial FA metabolism
and cardiac function in a non-obese animal model of T2DM,
namely GK rats. To that end, we performed in vivo Positron
Emission Tomography (PET) imaging to quantify myocardial
FA oxidation and utilization in GK rats in comparison to non-
diabetic control rats. In parallel, we performed
echocardiography (ECHO) with tissue Doppler imaging to
assess both cardiac structure and function. We then assayed
for the levels of NEFA’s and triglycerides (TG) in both plasma
and cardiac tissues. Finally, we performed quantitative PCR
(qPCR) arrays on select genes that have been implicated in
diabetes and FA metabolism to characterize alterations in gene
expression between non-obese GK and non-diabetic rats.
Materials and Methods
Animal Model and Study Design
Healthy male adult GK rats were obtained from Charles
River Laboratories. The standard Wistar rat serves as the
control model for GK rat (Charles River Laboratories,
Wilmington, MA). Both GK and Wistar rats were placed under
standard housing conditions and fed with commercial pelleted
chow ad libitum. Unless otherwise stated, all studies were
performed at 24 weeks of age. Quantitative PET imaging was
performed at two time-points: at 18 weeks of age with
Fluorodeoxyglucose (FDG) to characterize myocardial glucose
utilization, and at 24 weeks with [11C]Palmitate to characterize
myocardial FA metabolism. In addition, ECHO imaging was
performed to characterize cardiac structure and function. Gene
expression analysis was performed to garner mechanistic
insight. All experiments were conducted according to a protocol
approved by the animal experiment committee at Washington
University School of Medicine at Saint Louis (IACUC Animal
Welfare Assurance # A-3381-01) and in accordance to
‘Principles of laboratory animal care’ (NIH publication no. 85–
23, revised 1985; http://grants1.nih.gov/grants/olaw/references/
phspol.htm.
Rodent PET Imaging Protocol
All animals were fasted overnight (typically 10 hours) before
PET imaging. For the imaging experiments, rats (N=4/group)
were anesthetized with 1.5 - 2.0 % isoflurane in oxygen. The
animals were maintained at physiological body temperature
and breathing freely. Dynamic PET acquisition started five
seconds following a bolus tail vein injection of the
radiopharmaceutical. The imaging protocol consisted of a 20-
minute transmission scan to correct for attenuation, followed by
a 20-minute dynamic PET acquisition with [11C] Acetate (0.6–
0.8mCi) to quantify myocardial blood flow (MBF) [14,19] and
either 0.6-0.8mCi FDG (at 18wk) or 0.6-0.8mCi FDG
[11C]Palmitate (at 24wk) as described above. During each
imaging session, 5–6 whole-blood arterial samples were
collected from the femoral artery to measure whole blood
glucose (5 µL), NEFA and TG (20 µL), and insulin (5 µL) levels
as well as to correct for the presence of 11C metabolites, as
described below and in detail by Sharp et al [20]. In total, the
PET imaging protocol lasted 2 h.
Plasma & Tissue Substrates Determination
Cardiac tissue was isolated, pulverized and NEFA and TG
extracted from 1mg of sample using established procedures.
All substrates, insulin, and TG levels were measured using
commercially available kits by the Nutrition and Obesity
Research Center (NORC) or the Diabetes Research Center
(DRC) at Washington University School of Medicine (WUSM)
per manufacturers’ protocol.
Echocardiographic studies
Echocardiograms were performed using non-invasive
ultrasound imaging with the Vevo2100 Ultrasound System
(Visual Sonics Inc., Toronto, Ontario, Canada) at ages 23-24
weeks as described previously [14]. Briefly, rats (N=4-8/group)
were anesthetized with 1% isoflurane and secured to the
imaging platform. Complete 2-dimensional, M-mode, and
Doppler examinations using a 21 MHz transducer were
performed to quantify left ventricular structure as well as
diastolic and systolic function. All dimensional measurements
were indexed to body weight. Measures of left ventricular
structure were also used to determine partial volume
corrections performed in conjunction with kinetic modeling of
metabolic tracers (described below).
Pre-Clinical PET Image Quantification
Dynamic images were reconstructed using filtered back
projection with a 2.5 zoom on the heart and 40 frames per
imaging session. For ease of analysis, all dynamic imaging
frames were summed to one image. For each scan, regions of
interest were drawn over the left ventricle (LV) blood pool and
the anterolateral myocardium to minimize contamination from
the liver. Time activity curves were then generated for blood
and tissue in each study. To estimate the input function for
FDG, [11C]Acetate and [11C]Palmitate, the hybrid image blood
sampling algorithm [21] was employed.
MBF and myocardial glucose utilization were estimated as
described previously [19]. To estimate FA metabolism, a
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standard four-compartment, five-parameter model (see
supplemental material) was used to quantify [11C]Palmitate
kinetics in the heart [16]. Kinetic parameters K1-K5 were
estimated by optimizing 15 minutes of PET data to the
compartmental model. From parameter estimates, intrinsic and
extrinsic rates of FA oxidation, esterification and utilization can
be calculated (see supplemental material). Intrinsic rates are
independent of peripheral effects, i.e., plasma substrate levels,
whereas extrinsic rates are associated with flux and absolute
accumulation (e.g,, TG) based on the concentration of FA in
plasma. Intrinsic measures of FA metabolism are summarized
in the Supplemental section. Extrinsic myocardial FA oxidation
rate (MFAO), esterification rate (MFAE), total FA utilization rate
(MFAU), and tracer extraction fraction (EF), were calculated
based on the estimated rate constants (see Supplemental
Methods Section).
RNA Isolation and Real-Time RT-PCR
Cardiac tissues (N=4/group) were harvested and frozen at
−80°C until RNA isolation for gene-expression analysis was
performed. Total RNA was isolated from heart by using
RNEasy Lipid Tissue extraction kit (Qiagen, MD) according the
manufacturer’s protocol. RNA concentration, purity, and
integrity were determined by spectrophotometric analysis as
well as with an Agilent Bio-analyzer. First-strand cDNA was
generated by reverse transcription using 1μg total RNA and the
RT2 First Strand Kit. qPCR was conducted in 384 well plate
array format (FA metabolism (PARN-0007E) and Diabetes
(PARN-0023E), obtained from SA Biosciences. Real-time RT-
PCR was performed using the ABI PRISM 7900 HT system
and RT² SYBR Green qPCR Universal master mix with ROX as
passive reference dye (SA Biosciences, MD) as per
manufacturers protocol. Average readouts of housekeeping
genes; Rpl13a, Ldha, and Actb were used for normalizing the
data.
Statistics and Data analysis
Data processing and statistical analysis was done in either
MS Excel or Graphpad Prism (Graphpad software, La Jolla
CA). For qPCR analysis, Excel templates provided by SA
biosciences were used along with their web analysis tool
located at http://pcrdataanalysis.sabiosciences.com/pcr/
arrayanalysis.php. A 2-tailed student t-test was performed to
test for significant differences between groups. The data is
presented as mean ± SD unless noted otherwise. A P-value of
p<0.05 was considered significant.
Results
Hemodynamics, blood and tissue substrate levels
GK rats exhibited lower weight compared to Wistar rats
(Table 1). In agreement with published data [22], GK rats
exhibited elevated plasma glucose and decreased insulin
levels (Table 1), although the latter was not significantly
different, possibly due to the small sample size. GK rats also
showed marginally reduced heart rate. While GK rats generally
tended to have increased plasma NEFA and TG levels, they
were not significantly elevated. However, GK rats exhibited
76% and 57% higher cardiac tissue NEFA and TG levels,
respectively. Myocardial blood flow (MBF) estimated using PET
imaging, was significantly reduced (P<0.05) in GK rats relative
to Wistar rats (Table 1).
Cardiac Structure and Function
Structurally, all anatomical dimensions were indexed to body
weight (Table 2). In comparison to Wistar rats, GK rats display
increased left ventricle posterior wall thickness during both
diastole (LVPWId) and systole (LVPWIs); increased intra-
ventricular septal thickness in both the end-diastole (IVSId) and
end-systole (IVSIs); higher left ventricular mass index (LVMI, );
and higher left ventricular internal diameter index (LVIDId).
Taken together, these small, albeit significant, changes
indicated that GK rats developed mild LV hypertrophy
accompanied by mild LV chamber dilation. With respect to LV
function, fractional shortening (FS), a commonly used
parameter of systolic function in rodents, was not significantly
different between GK and Wistar groups. In contrast, we
observed reduced early left ventricular filling velocity (E) and a
reduction in LV filling velocity in the atrial component (A) in GK
rats relative to Wistar rats (Table 2). GK rats also had
decreased velocity of the early (E’) component of mitral annular
diastolic motion. These variations are consistent with diastolic
dysfunction. In addition, the Tei index, which is a temporal
parameter commonly used to describe global LV function (both
systolic and diastolic), was abnormally elevated in GK rats
compared with controls.
In vivo FA metabolism
GK rats exhibited nearly two-fold higher extrinsic MFAO
compared to Wistar rats (Figure 1A) with a marginal increase in
MFAE (Figure 1B) indicating that the majority of the increased
MFAU (Figure 1C) is attributed to FA oxidation. Intrinsic
measures of myocardial FA metabolism are provided in the
Supplementary section, but generally display a pattern similar
to that of extrinsic measures. Though MBF was almost twice as
low in GK rats compared to Wistars, we observed nearly two-
Table 1. Descriptive data, hemodynamics, and plasma
substrate levels.
 Wistar (n = 4) GK (n = 4 )
Weight (g) 491.67 ± 9.25 334.17 ± 17.78a
Insulin (μu/mL) 14.5 ± 9.98 12.32 ± 3.47
Glucose (mmol/L) 7.80 ± 0.74 9.86 ± 0.94b
HR (bpm) 370.33 ± 31.20 323.00 ± 47.69
MBF (mL/g/min) 4.32 ± 0.80 2.46 ± 0.33b
Cardiac NEFA (μmol/g of tissue) 0.76 ± 0.08 1.34 ± 0.44 b
Cardiac TG (μg/mg of tissue) 1.74 ± 0.60 2.74 ± 1.23 b
Plasma NEFA (μmol/L) 1084.5 ± 270.10 1434.25 ± 215.88
Plasma TG (μmol/L) 877.01 ± 269.67 1219.97 ± 206.75
Values given as mean ± SD. HR, Heart Rate; MBF, Myocardial Blood Flow.
a P<0.001, b P<0.05, significantly different than wistars
doi: 10.1371/journal.pone.0078477.t001
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fold increase in the EF of FA, i.e. the flux of FA utilized
normalized to that of MBF, as measured by PET (Figure 1D).
Gene Expression Analysis Panel
Differences in the expression of genes involved in FA
metabolism and diabetes were analyzed by qPCR. Statistical
analysis of the qPCR data yielded a list of significant genes
(P<0.05) for FA metabolism and Diabetes panels. The heat-
maps described below depict the fold change and their
functional grouping.
Expression profile of genes involved in Diabetes.  In the
diabetes array (Figure 2), 17 genes were significantly altered
between GK and Wistar rats. These significantly altered genes
represent diverse functional categories including metabolic
enzymes, signal transduction, receptors, and secreted factors.
Notably, resisitin (Retn) was down-regulated by more than 10-
fold in GK rats. We also observed that, Insulin receptor
substrate 1 (Irs1), dipeptidyl-peptidase (Dpp4) and Heme
oxygenase1 (Hmox) were down-regulated at varying levels,
Table 2. Echocardiographic measurements.
 Wistar (n = 4) GK (n = 4 )
Structural   
LVPWId (mm/kg) 3.69±0.56 4.94±1.00 b
LVPWIs (mm/kg) 5.96±0.72 7.35±1.29b
LVIDId (mm/kg) 15.32±2.03 21.91±2.11a
LVIDIs (mm/kg) 8.68±1.44 13.60±2.70a
LVMI (mg/g) 2.45 ± 0.31 2.84±0.36 b
IVSId (mm/kg) 4.03±0.62 4.80±0.93
IVSIs (mm/kg) 6.58±0.96 7.66±1.26
Functional   
FS (%) 43.45 ± 3.56 38.20 ± 8.89
E (mm/s) 1041.33 ± 164.08 818.50 ± 78.10b
A (mm/s) 813.67 ± 153.30 560.50 ± 77.88b
E/A 1.29 ± 0.11 1.49 ± 0.29
E' (mm/s) 54.43 ± 16.20 36.26 ± 13.54b
A' (mm/s) 51.35 ± 12.80 52.27 ± 11.95
E/E' 23.40 ± 10.05 26.84 ± 7.55
IVCT (ms) 10.98 ± 0.98 12.26 ± 1.25b
ET 61.51 ± 4.42 65.54 ± 6.23
IVRT (ms) 19.09 ± 3.10 24.88 ± 4.34a
Tei Index 0.49 ± 0.05 0.57 ± 0.11b
All dimensional measurements were indexed to body weight. IVS, Interventricular
septum; IVCT, Iso-volumic contraction time; IVRT, Iso-volumic relaxation time;
LVIDId, LV internal dimension index diastole; LVIDIs, LV internal dimension index
systole; LVMI, LV mass index; LVPWId, LV posterior wall index diastole;
LVPWIs,LV posterior wall thickness index systole. Functional: FS, fractional
shortening; E, peak velocity of early diastolic trans-mitral flow; A, peak velocity of
late (atria) diastolic trans-mitral flow; S', peak velocity of systolic mitral annular
motion; E', peak velocity of early diastolic mitral annular motion; A', peak velocity of
late (atrial) diastolic mitral annular motion; IVCT, iso-volumic contraction time; ET,
LV ejection time; IVRT, iso-volumic relaxation time; Tei Index, LV performance
index calculated as (IVCT+IVRT)/ET. Values given as mean ± SD (N=4-8/group). a
P<0.001, b P<0.05, significantly different than wistar rats.
doi: 10.1371/journal.pone.0078477.t002 while genes Mapk14, Nos3, Agt, Hnf1b Pparg exhibited up-
regulation in comparison to Wistar rats (Figure 3).
Alterations of genes involved in FA metabolism.  We
analyzed the expression of genes involved in FA transport,
activation, and the metabolic fate of FAs in GK rats. The
analysis indicated that 41 of the 84 genes involved in FA
metabolism were significantly altered (mostly up regulated) in
GK rats in comparison to Wistar rats (Figure 4). In particular,
several genes involved in FA transport and activation, (Acyl-
CoA synthetases, Fatp’s, Fabp’s, transferases) (Figure 5A); β-
oxidation, (dehydrogenases, and thioesterases) (Figure 5B);
TG biosynthesis and degradation, and ketogenesis (Figure 5C)
display elevated level of expression in GK rats compared to
Wistar rats.
Discussion
Epidemiological studies suggest a close link between obesity
and the increased incidence of T2DM in the USA and
worldwide. Accordingly, various animal models of obesity have
been reported and used in studying the interplay between
obesity and T2DM [23]. To study T2DM independent of obesity,
Figure 1.  PET measures of myocardial fatty acid
metabolism and blood flow.  (A) Extrinsic myocardial fatty
acid oxidation rate (MFAO) (B) Extrinsic myocardial fatty acid
esterification rate (MFAE), (C) Extrinsic myocardial fatty acid
utilization rate (MFAU), (D) myocardial Extraction Fraction (EF)
in GK and control rats. *denotes that GK rats are significantly
different (P<0.05) than Wistars for that measurement. All
results are presented as mean ± 1 SEM with N=4/group.
doi: 10.1371/journal.pone.0078477.g001
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we utilized GK rats—a polygenic animal model of T2DM—with
particular emphasis on interplay between T2DM and
myocardial FA metabolism and function. We performed ECHO
to assess cardiac function, quantitative PET imaging to
characterize FA metabolism, and qPCR to provide a
mechanistic insight on the functional, metabolic, and genomic
myocardial phenotype of GK rats.
In Vivo Functional and Metabolic Imaging
Echocardiographic measurements suggest that GK rats
develop mild structural remodeling of the LV and impaired
cardiac function in agreement with previously published reports
on GK rats [18,24]. In previous studies, and confirmed within,
GK rats exhibited reduced glucose uptake, which was
attributed to deficiencies in insulin signaling [17]. We performed
in vivo PET imaging to quantify both intrinsic and extrinsic
measures of cardiac FA metabolism [14,16]. The data suggest
that GK rats have higher FA utilization rates in comparison to
Wistar rats. The higher rate of FA utilization is attributed
primarily to higher FA oxidation rates. In addition, GK rats
exhibit higher MFAE, albeit not significant, in comparison to
Wistar rats, while cardiac TG was significantly higher in GK rats
in comparison to Wistar. While both cardiac TG measures and
PET-derived measures of MFAE exhibit similar trends, the
discrepancy in the magnitude can be explained by several
factors: 1) in estimating MFAE, it is assumed that the
metabolism of FA with various chain-lengths is similar to that of
C16 palmitate, which may not necessarily be the case. In fact,
oxidative substrate chain-length preference has been
documented [25,26]; and 2) cardiac TG content is the sum of
multiple sources of FA, including those derived from plasma
and those broken-down from plasma TG and re-esterified in
tissue. PET measures of MFAE, however, primarily reflect
metabolism of plasma FA since [11C] Palmitate is introduced in
the bloodstream. FA derived from lipolysis of plasma TG may
also be reflected in MFAE, depending on functional pools of
available NEFA. Taken together, in vivo data suggests that GK
rats have an innate preference for FAs in comparison to Wistar
rats. To gain mechanistic insight for differences in FA
metabolism between GK and control rats, we performed qPCR
on a panel on genes implicated in diabetes as well as select
genes involved in FA metabolism.
Differential Expression of Genes Implicated in Diabetes
Expression analysis of genes implicated in diabetes indicates
differential expression of several genes encoding receptors,
transcription factors, and metabolic enzymes. Of particular note
is resistin, a hormone that links inflammation, insulin resistance
and coronary heart disease [27], which is down-regulated more
than 10-fold in GK rats. The heart is thought to be a resistin
target where it enhances phosphorylation of insulin receptor
substrate-1 and thus insulin resistance, impacting glucose
transport [28]. It has been observed that resistin’s action is
modulated, at least in part by TNF-α [29], which is also down-
regulated in our analysis. We observed down-regulation of
Dpp4 which is known to alter post-prandial lipid levels [30]. Agt,
coding angiotensinogen involved in production of Ang I and
subsequently Ang II, which has been shown to regulate
triglyceride biosynthesis, is up-regulated [31]. Taken together
Figure 2.  Clustering and functional grouping of genes involved in diabetes.  (A) Heat map and Gene correlation clusters of
genes involved in diabetes including; transcription factors, metabolic enzymes, Receptors and secreted factors. Gene correlation
clusters were calculated using the Spearman Correlation Distances and complete linkage for hierarchical clustering. Data for
individual biological replicates are shown at the 95% or above confidence level. (B) Pie chart illustrating functional distribution of
genes involved in diabetes and varies between GK and Wistar rats. (N=4/group).
doi: 10.1371/journal.pone.0078477.g002
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these data support the notion that the cardiac tissues in GK
rats have an altered metabolic preference.
Differential Expression of Genes Involved in FA
Metabolism
Activation of FAs is a key step in FA oxidation and is
catalyzed by acyl-CoA synthetases. Carnitine palmitoyl
transferase 2 (CPT2), Carnitine acetyl transferase (CRAT), and
Figure 3.  Differential expression of genes involved in
diabetes.  RNA from N=4/group rats were isolated and
expression analyzed using PCR array from SA Biosciences. All
results are presented fold change (mean ± 1SD) relative to
Wistar rats. *P<0.05, #P<0.01 ‡P<0.001 denotes significance
(Students’t-Test).
doi: 10.1371/journal.pone.0078477.g003
Carnitine O-octanoyl transferase (CROT) are key enzymes
involved in activated FA transport to the mitochondria. We
observed increased expression of these genes along with
several other FA transporters (Fabp’s and Fatp’s). Post entry
into the mitochondria, chain-length specific Acyl-CoA
dehydrogenases (ACADs) carry out the first step of
mitochondrial beta-oxidation. Indeed, we observe increased
expression of several ACADs in agreement PET measures of
MFAO. Gene encoding for lipoprotein lipase (LPL), which is
involved in the hydrolysis of lipoproteins, is similarly up-
regulated in the GK rats along with hormone-sensitive lipase
(HSL). Conversely, Gpd1, Gpd2 and Gk which are involved in
TG biosynthesis are up-regulated as well. Combined increase
in genes involved in TG hydrolysis and biosynthesis suggests
continuous lipolysis and biosynthesis of TG, as observed
previously [32]. Moreover, in addition to plasma NEFA as a
source for TG formation, hydrolysis of plasma TG by LPL may
further contribute to the cardiac TG pool resulting in an overall
net accumulation of TG in the heart. Accordingly, we observed
increased MFAE, notwithstanding potential discrepancies
between PET measures of TG and cardiac TG discussed
above. In conclusion, our data suggest increased mobilization
of resources resulting in increasing FA metabolism.
Interestingly, we observed increased expression of genes
involved in ketogenesis, namely Bdh1, Bdh2, Hmgcl, Hmgcs1,
and Hmgcs2. Ketone bodies such as acetoacetate and β-
hydroxybutyrate predominantly act as water soluble
equivalents of FA to power peripheral tissues like heart and
skeletal muscle. Increase in ketone metabolism may be a
feature of the failing heart, as has been demonstrated
previously [33].
Conclusion
In conclusion, our data support the notion that GK rats
exhibit functional, metabolic and genomic differences in FA
utilization independent of obesity. Functionally, GK rats
exhibited structural remodeling and impaired cardiac function.
Metabolically, GK rats exhibited increased FA utilization
measured with quantitative metabolic imaging. The increase in
FA utilization was primarily attributed to increased FA
oxidation. Gene expression analysis on GK rats suggests a
molecular signature of altered cardiac substrate preference,
favoring increased fatty acid utilization. Taken together, the
insights presented within may be used to devise targeted
screening and therapeutic strategies for diabetes in the
absence of the confounding factors of obesity, which are
present in most animal models of Type 2 Diabetes.
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Figure 4.  Clustering and functional grouping of genes involved in fatty acid metabolism.  (A-D) Heat map and Gene
correlation clusters of genes involved in FA Metabolism including; fatty acid catabolism(A), fatty acid transport (B), triglyceride
biosynthesis (C), and ketogenesis (D). Gene correlation clusters were calculated using the Spearman Correlation Distances and
complete linkage for hierarchical clustering. Data for individual biological replicates are shown at the 95% or above confidence level.
(E) Pie chart illustrating functional distribution of genes involved in FA metabolism in heart and varies between GK and Wistar rats.
(N=4/group). .
doi: 10.1371/journal.pone.0078477.g004
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Figure 5.  Differential expression of genes involved in fatty acid metabolism.  RNA from (N=4/group) rats were isolated and
expression analyzed as mentioned earlier. The fold changes of genes grouped based on their function; Fatty acid transport (A),
Fatty acid catabolism (B), Ketogenesis and TG metabolism (C), are presented here. All results are presented fold change (mean ±
1SD) relative to Wistar rats. *P<0.05, #P<0.01 ‡P<0.001 denotes significance (Students’t-Test).
doi: 10.1371/journal.pone.0078477.g005
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Supporting Information
Text S1.  In vivo quantification of myocardial fatty acid
metabolism using [11C]Palmitate.
(DOCX)
Figure S1.  Five-compartment, six-parameter model of [11C]
Palmitate kinetics. Cp: Tracer concentration in plasma; C1:
extracelluar tracer concentration; C2: cytosolic tracer
concentration; C3: esterified tracer concentration; C4: oxidized
tracer concentration; k1-k5, kinetic rate constants (min-1).
(TIF)
Figure S2.  Quantification of myocardial glucose utilization
(MGU) in GK and Wistar rats.
(TIF)
Figure S3.  Intrinsic measures of myocardial fatty acid
metabolism as measured by PET. (A) intrinsic myocardial
fatty acid oxidation rate (MFAOUpR) (B) intrinsic myocardial
fatty acid esterification rate (MFAEUpR), (C) intrinsic
myocardial utilization (MFAUUpR) in GK and control rats.
MFAOUpR, MFAEUpR and MFAUUpR represent the intrinsic
capacity of the heart to oxidize, esterify and utilize fatty acids,
respectively, independent of the concentration of free fatty
acids in plasma. *denotes that GK rats are significantly different
(P<0.05) than Wistars for that measurement. All results are
presented as mean ± 1 SEM with N=4/group.
(TIF)
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